Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical ...

The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024 ... treatment simplifies clinical procedure by eliminating the need for ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...

And then at ESMO, of course, we have the plenary presentation ... cystectomy is a very difficult procedure. Sounds quite horrible. How real world is this trial then? You said, I mean, 85% of ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

The global collective intelligence network aims to accelerate precision oncology research and care ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...